SG11201809959PA - Methods of decreasing trisulfide bonds during recombinant production of polypeptides - Google Patents

Methods of decreasing trisulfide bonds during recombinant production of polypeptides

Info

Publication number
SG11201809959PA
SG11201809959PA SG11201809959PA SG11201809959PA SG11201809959PA SG 11201809959P A SG11201809959P A SG 11201809959PA SG 11201809959P A SG11201809959P A SG 11201809959PA SG 11201809959P A SG11201809959P A SG 11201809959PA SG 11201809959P A SG11201809959P A SG 11201809959PA
Authority
SG
Singapore
Prior art keywords
media
international
cystine
polypeptides
cysteine
Prior art date
Application number
SG11201809959PA
Inventor
Martin Gawlitzek
Sven Markert
Oliver Popp
Masaru Shiratori
Thomas Troebs
Jessica Wuu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG11201809959PA publication Critical patent/SG11201809959PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111111111111111111111111111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/196902 A3 16 November 2017 (16.11.2017) WIPO I PCT (51) International Patent Classification: (72) Inventors: GAWLITZEK, Martin; c/o Genentech, Inc., 1 C12P 21/08 (2006.01) DNA Way, South San Francisco, CA 94080 (US). MARK- ERT, Sven; Penzberger Str. 16, 82404 Sindelsdorf (DE). (21) International Application Number: POPP, Oliver; Floesserstr. 15, 82377 Penzberg (DE). PCT/US2017/031832 SHIRATORI, Masaru, Ken; c/o Genentech, Inc., 1 Dna (22) International Filing Date: Way, South San Francisco, CA 94080 (US). TROBES, 09 May 2017 (09.05.2017) Thomas; Demleitnerstr. 23, 81371 Muenchen (DE). WUU, Jessica; c/o Genentech, Inc., 1 DNA Way, South San Fran- (25) Filing Language: English cisco, CA 94080 (US). (26) Publication Language: English (74) Agent: ONUFRYK, Christina et al.; Morrison & Foerster (30) Priority Data: LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US). 62/334,433 10 May 2016 (10.05.2016) US (81) Designated States (unless otherwise indicated, for every (71) Applicant (for all designated States except AL, AT, BA, kind of national protection available): AE, AG, AL, AM, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR): GENEN- DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, TECH, INC. [US/US]; 1 DNA Way, South San Francisco, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, CA 94080-4990 (US). KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (71) Applicant (for AL, AT, BE, BG, CH, CN, CY, CZ, DE, DK, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, = SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, = MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. only): F. HOFFMANN-LA ROCHE AG [CH/CH]; Gren- = zacherstrasse 124, 4070 Basel (CH). = = Title: METHODS OF DECREASING TRISULFIDE BONDS DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES (54) FIG. 1 = = = 50 = = _ 40 _ = < —F—Media 1, cysteine + Fe E —II—Media 1, cystine + Fe = E 30 ' —O-Media 2, cysteine + Fe = —0—Media 2, cystine, + Fe = Z 7.—Media 1, cysteine 20 • —0—Media 1, cystine —c—Media 2, cysteine en 10 —#— Media 2, cystine ei © 0 irr • cT 0 12 24 36 48 60 72 t:T 1-1 Time (hours) Ir - - 1-1 N (57) : Provided herein are cell culture media and methods culturing host cells expressing polypeptides to reduce the level of trisulfide bonds in polypeptides produced by the host cells. [Continued on next page] WO 2017/196902 A3 MUNRO DOI 01011MMEM31111111111 1111111101101 1111111110fin (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, F1, FR, GB, GR, HR, HU, 1E, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) (88) Date of publication of the international search report: 22 February 2018 (22.02.2018)
SG11201809959PA 2016-05-10 2017-05-09 Methods of decreasing trisulfide bonds during recombinant production of polypeptides SG11201809959PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662334433P 2016-05-10 2016-05-10
PCT/US2017/031832 WO2017196902A2 (en) 2016-05-10 2017-05-09 Methods of decreasing trisulfide bonds during recombinant production of polypeptides

Publications (1)

Publication Number Publication Date
SG11201809959PA true SG11201809959PA (en) 2018-12-28

Family

ID=59034843

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809959PA SG11201809959PA (en) 2016-05-10 2017-05-09 Methods of decreasing trisulfide bonds during recombinant production of polypeptides

Country Status (13)

Country Link
US (1) US20190169667A1 (en)
EP (1) EP3455364A2 (en)
JP (4) JP7181091B2 (en)
KR (2) KR20190005966A (en)
CN (2) CN114703244A (en)
AR (1) AR108436A1 (en)
AU (1) AU2017264754A1 (en)
BR (1) BR112018073133A2 (en)
CA (1) CA3022955A1 (en)
IL (1) IL262781A (en)
MX (1) MX2018013683A (en)
SG (1) SG11201809959PA (en)
WO (1) WO2017196902A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020077169A1 (en) * 2018-10-12 2020-04-16 Trican Biotechnology Co., Ltd Bi-functional fusion proteins and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2096590T3 (en) 1989-06-29 1997-03-16 Medarex Inc BI-SPECIFIC REAGENTS FOR AIDS THERAPY.
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE139258T1 (en) 1990-01-12 1996-06-15 Cell Genesys Inc GENERATION OF XENOGENE ANTIBODIES
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DE69308573T2 (en) 1992-08-17 1997-08-07 Genentech Inc SPECIFIC IMMUNOADHESINE
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP4312259B2 (en) 1995-04-27 2009-08-12 アムジェン フレモント インク． Human antibodies derived from immunized XenoMouse
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
PT2275119E (en) 1995-07-27 2013-11-21 Genentech Inc Stable isotonic lyophilized protein formulation
WO1998015624A1 (en) * 1996-10-09 1998-04-16 Human Genome Sciences, Inc. Galectin 8, 9, 10 and 10sv
KR100643058B1 (en) 1996-12-03 2006-11-13 아브게닉스, 인크. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
WO1998056418A1 (en) 1997-06-13 1998-12-17 Genentech, Inc. Stabilized antibody formulation
KR100816572B1 (en) * 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Anti-VEGF antibody and a pharmaceutical composition comprising the same
US20040048315A1 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
JP5687057B2 (en) * 2007-07-09 2015-03-18 ジェネンテック， インコーポレイテッド Prevention of disulfide bond reduction during recombinant production of polypeptides.
US9005926B2 (en) 2009-10-02 2015-04-14 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
MX2012012525A (en) 2010-04-26 2012-11-23 Novartis Ag Improved cell culture medium.
US9562252B2 (en) * 2011-05-13 2017-02-07 Biogen Ma Inc. Methods of preventing and removing trisulfide bonds
US8759794B2 (en) 2012-07-20 2014-06-24 Honeywell International Inc. Articles, methods of validating the same, and validation systems employing decay constant modulation
CN103152739A (en) 2013-02-06 2013-06-12 北京奇虎科技有限公司 Method, device and system for processing calling request information of mobile terminal
BR112015021993A8 (en) * 2013-03-15 2019-12-03 Genentech Inc polypeptide, methods for producing it, methods for culturing a cell, pharmaceutical composition, kit, and cell culture medium
EP3122771A1 (en) 2014-03-27 2017-02-01 F. Hoffmann-La Roche AG Anti-influenza b virus hemagglutinin antibodies and methods of use
MA40682B1 (en) 2014-03-31 2020-01-31 Hoffmann La Roche Anti-ox40 antibodies and methods of use thereof
US9765135B2 (en) 2014-12-19 2017-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies
JP7001585B2 (en) * 2015-09-23 2022-02-04 ファイザー・インク Cell and cell culture methods

Also Published As

Publication number Publication date
KR20230124093A (en) 2023-08-24
MX2018013683A (en) 2019-06-17
JP7181091B2 (en) 2022-11-30
WO2017196902A3 (en) 2018-02-22
AU2017264754A1 (en) 2018-12-13
WO2017196902A2 (en) 2017-11-16
CA3022955A1 (en) 2017-11-16
KR20190005966A (en) 2019-01-16
EP3455364A2 (en) 2019-03-20
IL262781A (en) 2018-12-31
JP2024001018A (en) 2024-01-09
BR112018073133A2 (en) 2019-04-30
US20190169667A1 (en) 2019-06-06
AR108436A1 (en) 2018-08-22
CN114703244A (en) 2022-07-05
CN109154014A (en) 2019-01-04
JP2019514412A (en) 2019-06-06
JP2023027081A (en) 2023-03-01
JP2022000032A (en) 2022-01-04

Similar Documents

Publication Publication Date Title
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201809710RA (en) Genetically engineered cells and methods of making the same
SG11201805162VA (en) Plasmid constructs for heterologous protein expression and methods of use
SG11201907846VA (en) Therapeutic rna
SG11201808196UA (en) Neoantigens and methods of their use
SG11201908787WA (en) Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
SG11201805451TA (en) Immune effector cell therapies with enhanced efficacy
SG11201811048UA (en) Single-cell transcript sequencing
SG11201807538PA (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
SG11201811405QA (en) Improved differentiation method
SG11201406903SA (en) Cell culture compositions and methods for polypeptide production
SG11201906213UA (en) Modulating expression of polypeptides via new gene switch expression systems
SG11201804127SA (en) Ctla4 binders
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201807114TA (en) Colony forming medium and use thereof
SG11201805052YA (en) Therapeutic methods using erythrocytes
SG11201407866XA (en) Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector
SG11201901228QA (en) Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
SG11201900361RA (en) Methods of treating prostate cancer
SG11201803918VA (en) Production of steviol glycosides in recombinant hosts
SG11201904535VA (en) Prevention and treatment of bone and cartilage damage or disease